Bleakley Financial Group LLC Makes New $126,000 Investment in Haleon plc (NYSE:HLN)

Bleakley Financial Group LLC purchased a new position in Haleon plc (NYSE:HLN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,863 shares of the company’s stock, valued at approximately $126,000.

A number of other large investors also recently modified their holdings of HLN. Cultivar Capital Inc. acquired a new position in shares of Haleon in the 2nd quarter worth approximately $40,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Haleon during the first quarter worth approximately $43,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Haleon by 29.8% during the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after purchasing an additional 1,421 shares during the period. Hexagon Capital Partners LLC lifted its stake in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after acquiring an additional 2,677 shares during the last quarter. Finally, BOKF NA lifted its stake in Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Trading Down 0.2 %

Shares of Haleon stock opened at $9.89 on Friday. The firm has a market capitalization of $45.14 billion, a PE ratio of 32.95, a price-to-earnings-growth ratio of 2.93 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company’s fifty day moving average price is $10.23 and its two-hundred day moving average price is $9.18. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same period last year, the firm earned $0.08 EPS. On average, analysts expect that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HLN. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Haleon currently has a consensus rating of “Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.